Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis

NEWARK, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
June 17, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference

NEWARK, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
June 11, 2019 07:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis

- Reductions in liver fat were minimal and not significant compared to placebo- Reductions in markers of liver injury were robust and clinically meaningful- Seladelpar appears to be safe and...
May 20, 2019 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019

NEWARK, Calif., May 20, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
May 08, 2019 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update

NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
May 08, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Multiple Presentations at DDW 2019

NEWARK, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the...
April 30, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8

NEWARK, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
April 12, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019

NEWARK, Calif., April 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
March 27, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019

NEWARK, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver...
March 12, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at Upcoming Investor Conferences in March

NEWARK, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative...